Linezolid 600 mg Tablets

Linezolid 600 mg Tablets

Product Details:

  • Ingredients Inactive ingredients are sodium citrate, citric acid, and dextrose in an aqueous vehicle for intravenous administration. The sodium (Na+) content is 0.38 mg/mL (5 mEq/300-mL bag and 1.7 mEq/100-mL bag). LINZOLON Tablet for oral administration contains 600 mg linezolid as a film-coated compressed tablet.
  • Physical Form Tablets
  • Function Antibiotic Medicine
  • Recommended For Suitable For All
  • Dosage As directed by the Dietician
  • Dosage Guidelines After Food
  • Quantity 500 Boxes
  • Click to View more
X

Linezolid 600 mg Tablets Price And Quantity

  • 500 Box
  • 450 INR

Linezolid 600 mg Tablets Product Specifications

  • Antibiotic Medicine
  • Tablets
  • 500 Boxes
  • store in a cool & dry ,dark plase
  • Suitable For All
  • As directed by the Dietician
  • Inactive ingredients are sodium citrate, citric acid, and dextrose in an aqueous vehicle for intravenous administration. The sodium (Na+) content is 0.38 mg/mL (5 mEq/300-mL bag and 1.7 mEq/100-mL bag). LINZOLON Tablet for oral administration contains 600 mg linezolid as a film-coated compressed tablet.
  • After Food

Linezolid 600 mg Tablets Trade Information

  • AS PER MARKET DEMANDS Per Day
  • 30/45 Days
  • Yes
  • Within a certain price range free samples are available
  • 10*10
  • All India
  • Drug Licence, WHO GMP Certified, FSSAI,

Product Description

Uses

Linezolid is an antibiotic used to treat certain serious bacterial infections. It works by stopping the growth of bacteria.

This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Linezolid also belongs to a class of drugs known as MAO inhibitors. It can increase the levels of certain natural substances in the body (such as dopamine, norepinephrine, serotonin) which can increase the chance of certain side effects and food and drug interactions. See How to Use, Side Effects, and Drug Interactions sections for more details.

 How to use Linezolid Tablet

Take this medication by mouth with or without food as directed by your doctor, usually every 12 hours. The dosage is based on your medical condition and response to treatment. For children, the dosage is also based on age and weight, and they may be directed to take this medication every 8 hours.

To prevent a very serious high blood pressure reaction, it is very important that you follow a special diet recommended by your doctor or dietician to limit your intake of tyramine while you are taking this medicine. Avoid foods and beverages that are high in tyramine, including aged cheeses, dried/aged meats and sausages (such as salami, liverwurst), preserved fish (such as pickled herring), products that contain large amounts of yeast (such as bouillon cubes, powdered soup/gravy, homemade or sourdough bread), fermented foods (such as sauerkraut, kim chee), most soybean products (such as soy sauce, tofu), broad/fava beans, red wine, sherry, tap beers, and vermouth. Consult your doctor or dietician for more details and a complete list of other foods that contain tyramine which you should limit or avoid.

For the best effect, take this antibiotic at evenly spaced times. To help you remember, take this medication at the same time(s) every day.

Continue to take this medication until the full prescribed amount is finished, even if symptoms disappear after a few days. Stopping the medication too early may result in a return of the infection.

 Usual Adult Dose for:

  • Bacteremia

  • Pneumonia

  • Bacterial Infection

  • Nosocomial Pneumonia

  • Skin and Structure Infection

 Usual Pediatric Dose for:

  • Bacteremia

  • Pneumonia

  • Bacterial Infection

  • Nosocomial Pneumonia

  • Skin and Structure Infection

Additional dosage information:

  • Renal Dose Adjustments

  • Liver Dose Adjustments

  • Precautions

  • Dialysis

  • Other Comments

 Usual Adult Dose for Bacteremia

  • 600 mg IV or orally every 12 hours


Duration of therapy:

  • Pneumonia: 10 to 14 consecutive days
  • Vancomycinresistant Enterococcus faecium infections: 14 to 28 consecutive days
  • Uses: For the treatment of communityacquired pneumonia due to Streptococcus pneumoniae (including cases with concurrent bacteremia) or Staphylococcus aureus (methicillinsusceptible isolates only); for the treatment of nosocomial pneumonia due to S aureus (methicillinsusceptible and resistant isolates) or S pneumoniae; for the treatment of vancomycinresistant E faecium infections (including cases with concurrent bacteremia)

 Usual Adult Dose for Pneumonia

  • 600 mg IV or orally every 12 hours

Duration of therapy:

  • Pneumonia: 10 to 14 consecutive days
  • Vancomycinresistant Enterococcus faecium infections: 14 to 28 consecutive days
  • Uses: For the treatment of communityacquired pneumonia due to Streptococcus pneumoniae (including cases with concurrent bacteremia) or Staphylococcus aureus (methicillinsusceptible isolates only); for the treatment of nosocomial pneumonia due to S aureus (methicillinsusceptible and resistant isolates) or S pneumoniae; for the treatment of vancomycinresistant E faecium infections (including cases with concurrent bacteremia)

 Usual Adult Dose for Bacterial Infection

  • 600 mg IV or orally every 12 hours
  • Duration of therapy:
  • Pneumonia: 10 to 14 consecutive days
  • Vancomycinresistant Enterococcus faecium infections: 14 to 28 consecutive days
  • Uses: For the treatment of communityacquired pneumonia due to Streptococcus pneumoniae (including cases with concurrent bacteremia) or Staphylococcus aureus (methicillinsusceptible isolates only); for the treatment of nosocomial pneumonia due to S aureus (methicillinsusceptible and resistant isolates) or S pneumoniae; for the treatment of vancomycinresistant E faecium infections (including cases with concurrent bacteremia)

 Usual Adult Dose for Nosocomial Pneumonia

  • 600 mg IV or orally every 12 hours
  • Duration of therapy:
  • Pneumonia: 10 to 14 consecutive days
  • Vancomycinresistant Enterococcus faecium infections: 14 to 28 consecutive days
  • Uses: For the treatment of communityacquired pneumonia due to Streptococcus pneumoniae (including cases with concurrent bacteremia) or Staphylococcus aureus (methicillinsusceptible isolates only); for the treatment of nosocomial pneumonia due to S aureus (methicillinsusceptible and resistant isolates) or S pneumoniae; for the treatment of vancomycinresistant E faecium infections (including cases with concurrent bacteremia)

 Usual Adult Dose for Skin and Structure Infectiom

  • Complicated infections: 600 mg IV or orally every 12 hours
  • Uncomplicated infections: 400 mg orally every 12 hours
  • Duration of therapy: 10 to 14 consecutive days
  • Uses: For the treatment of complicated skin and skin structure infections (including diabetic foot infections, without concomitant osteomyelitis) due to S aureus (methicillinsusceptible and resistant isolates), S pyogenes, or S agalactiae; for the treatment of uncomplicated skin and skin structure infections due to S aureus (methicillinsusceptible isolates only) or S pyogenes

 Usual Pediatric Dose for Bacteremia

  • Less than 7 days, gestational age less than 34 weeks: 10 mg/kg IV or orally every 12 hours
  • Less than 7 days, gestational age at least 34 weeks: 10 mg/kg IV or orally every 8 hours
  • 7 days through 11 years: 10 mg/kg IV or orally every 8 hours
  • 12 years or older: 600 mg IV or orally every 12 hours
  • Maximum dose: 600 mg/dose
  • Duration of therapy:
  • Pneumonia: 10 to 14 consecutive days
  • Vancomycinresistant E faecium infections: 14 to 28 consecutive days

Comments:

  • In preterm neonates younger than 7 days (gestational age less than 34 weeks) with suboptimal clinical response, may consider using 10 mg/kg every 8 hours
  • Maximum pediatric dose should not exceed recommended adult dose.
  • Uses: For the treatment of communityacquired pneumonia due to S pneumoniae (including cases with concurrent bacteremia) or S aureus (methicillinsusceptible isolates only); for the treatment of nosocomial pneumonia due to S aureus (methicillinsusceptible and resistant isolates) or S pneumoniae; for the treatment of vancomycinresistant E faecium infections (including cases with concurrent bacteremia)

Usual Pediatric Dose for Pneumonia

  • Less than 7 days, gestational age less than 34 weeks: 10 mg/kg IV or orally every 12 hours
  • Less than 7 days, gestational age at least 34 weeks: 10 mg/kg IV or orally every 8 hours
  • 7 days through 11 years: 10 mg/kg IV or orally every 8 hours
  • 12 years or older: 600 mg IV or orally every 12 hours
  • Maximum dose: 600 mg/dose
  • Duration of therapy:
  • Pneumonia: 10 to 14 consecutive days
  • Vancomycinresistant E faecium infections: 14 to 28 consecutive days

Comments:

  • In preterm neonates younger than 7 days (gestational age less than 34 weeks) with suboptimal clinical response, may consider using 10 mg/kg every 8 hours
  • Maximum pediatric dose should not exceed recommended adult dose.
  • Uses: For the treatment of communityacquired pneumonia due to S pneumoniae (including cases with concurrent bacteremia) or S aureus (methicillinsusceptible isolates only); for the treatment of nosocomial pneumonia due to S aureus (methicillinsusceptible and resistant isolates) or S pneumoniae; for the treatment of vancomycinresistant E faecium infections (including cases with concurrent bacteremia)

 Usual Pediatric Dose for Bacterial Infection

  • Less than 7 days, gestational age less than 34 weeks: 10 mg/kg IV or orally every 12 hours
  • Less than 7 days, gestational age at least 34 weeks: 10 mg/kg IV or orally every 8 hours
  • 7 days through 11 years: 10 mg/kg IV or orally every 8 hours
  • 12 years or older: 600 mg IV or orally every 12 hours
  • Maximum dose: 600 mg/dose
  • Duration of therapy:
  • Pneumonia: 10 to 14 consecutive days
  • Vancomycinresistant E faecium infections: 14 to 28 consecutive days

Comments:

  • In preterm neonates younger than 7 days (gestational age less than 34 weeks) with suboptimal clinical response, may consider using 10 mg/kg every 8 hours
  • Maximum pediatric dose should not exceed recommended adult dose.
  • Uses: For the treatment of communityacquired pneumonia due to S pneumoniae (including cases with concurrent bacteremia) or S aureus (methicillinsusceptible isolates only); for the treatment of nosocomial pneumonia due to S aureus (methicillinsusceptible and resistant isolates) or S pneumoniae; for the treatment of vancomycinresistant E faecium infections (including cases with concurrent bacteremia)

 Usual Pediatric Dose for Nosocomial Pneumonia

  • Less than 7 days, gestational age less than 34 weeks: 10 mg/kg IV or orally every 12 hours
  • Less than 7 days, gestational age at least 34 weeks: 10 mg/kg IV or orally every 8 hours
  • 7 days through 11 years: 10 mg/kg IV or orally every 8 hours
  • 12 years or older: 600 mg IV or orally every 12 hours
  • Maximum dose: 600 mg/dose
  • Duration of therapy:
  • Pneumonia: 10 to 14 consecutive days
  • Vancomycinresistant E faecium infections: 14 to 28 consecutive days

Comments:

  • In preterm neonates younger than 7 days (gestational age less than 34 weeks) with suboptimal clinical response, may consider using 10 mg/kg every 8 hours
  • Maximum pediatric dose should not exceed recommended adult dose.
  • Uses: For the treatment of community acquired pneumonia due to S pneumoniae (including cases with concurrent bacteremia) or S aureus (methicillin susceptible isolates only); for the treatment of nosocomial pneumonia due to S aureus (methicillinsusceptible and resistant isolates) or S pneumoniae; for the treatment of vancomycinresistant E faecium infections (including cases with concurrent bacteremia)

 Usual Pediatric Dose for Skin and Structure Infection

Complicated infections:

  • Less than 7 days, gestational age less than 34 weeks: 10 mg/kg IV or orally every 12 hours
  • Less than 7 days, gestational age at least 34 weeks: 10 mg/kg IV or orally every 8 hours
  • 7 days through 11 years: 10 mg/kg IV or orally every 8 hours
  • 12 years or older: 600 mg IV or orally every 12 hours

Uncomplicated infections:

  • Less than 7 days, gestational age less than 34 weeks: 10 mg/kg orally every 12 hours
  • Less than 7 days, gestational age at least 34 weeks: 10 mg/kg orally every 8 hours
  • 7 days to less than 5 years: 10 mg/kg orally every 8 hours
  • 5 through 11 years: 10 mg/kg orally every 12 hours
  • 12 years or older: 600 mg orally every 12 hours
  • Maximum dose: 600 mg/dose
  • Duration of therapy: 10 to 14 consecutive days

Comments:

  • In preterm neonates younger than 7 days (gestational age less than 34 weeks) with suboptimal clinical response, may consider using 10 mg/kg every 8 hours
  • Maximum pediatric dose should not exceed recommended adult dose.
  • Uses: For the treatment of complicated skin and skin structure infections (including diabetic foot infections, without concomitant osteomyelitis) due to S aureus (methicillinsusceptible and resistant isolates), S pyogenes, or S agalactiae; for the treatment of uncomplicated skin and skin structure infections due to S aureus (methicillinsusceptible isolates only) or S pyogenes

 Renal Dose Adjustments

  • No adjustment recommended.
  • Comments: Use in patients with renal dysfunction should be weighed against the potential risks of accumulation of the metabolites; clinical significance of such accumulation has not been established.

 Liver Dose Adjustments

  • Mild to moderate hepatic insufficiency (ChildPugh class A or B): No adjustment recommended.
  • Severe hepatic impairment: Data not available

 Precautions

  • Consult WARNINGS section for additional precautions.

 Dialysis

  • Hemodialysis: Dose should be administered after dialysis.
  • Peritoneal dialysis: Data not available
  • Comments:  About 30% of dose removed in 3hour hemodialysis session beginning 3 hours after dose administered.

 Other Comments

Administration advice:

  • IV injection: Administer via IV infusion over 30 to 120 minutes; do not use this IV infusion bag in series connections.
  • IV injection: When using concomitantly with another drug, administer each drug separately (as appropriate for each drug); if the same IV line is used for sequential infusion of several drugs, flush the line with a compatible infusion solution before and after infusion of this drug.
  • Do not adjust dose when switching from IV to oral administration (no adjustments needed).
  • Oral: May administer without regard to food
  • Oral suspension: Before use, gently mix by inverting the bottle 3 to 5 times; do not shake.
  • Do not use this drug for the treatment of gramnegative infections; if concomitant gramnegative pathogen verified/suspected, it is crucial that specific gramnegative therapy is started immediately.

Storage requirements:

  • Store at 25C (77F) and protect from light.
  • Keep bottles closed tightly to protect from moisture.
  • Keep infusion bags in overwrap until ready to use; protect from freezing.
  • Discard the oral suspension 21 days after constitution.
  • Reconstitution/preparation techniques:
  • The manufacturer product information should be consulted.

IV compatibility:

  • Compatible IV solutions: 0.9% Sodium Chloride Injection, USP; 5% Dextrose Injection, USP; Lactated Ringer's Injection, USP
  • Chemically incompatible: Ceftriaxone sodium
  • Physically incompatible: Amphotericin B, chlorpromazine hydrochloride, diazepam, pentamidine isethionate, erythromycin lactobionate, phenytoin sodium, sulfamethoxazoletrimethoprim
  • Additives should not be added to this IV solution.

General:

  • To reduce the development of drugresistant organisms and maintain effective therapy, this drug should be used only to treat or prevent infections proven or strongly suspected to be caused by susceptible bacteria. This drug has no clinical activity against gramnegative organisms.
  • Culture and susceptibility information should be considered when selecting/modifying antibacterial therapy or, if no data are available, local epidemiology and susceptibility patterns may be considered when selecting empiric therapy.
  • The safety and efficacy of this drug beyond 28 days have not been established.

Monitoring:

  • Cardiovascular: For potential blood pressure increases (the manufacturer product information should be consulted regarding patient population)
  • Hematologic: CBC (weekly)
  • Nervous System: For signs/symptoms of serotonin syndrome or neuroleptic malignant syndromelike reactions (the manufacturer product information should be consulted regarding patient population and monitoring duration)
  • Ocular: Visual function (the manufacturer product information should be consulted for further guidance)

Patient advice:

  • Avoid missing doses and complete the entire course of therapy.
  • Avoid ingesting large amounts of foods or beverages with high tyramine content (e.g., aged cheese, fermented or air dried meats, sauerkraut, soy sauce, tap beer, red wines) while using this drug.
  • Consult physician if changes in vision occur.
  • If you have phenyl ketonuria, be aware that the oral suspension contains 20 mg phenylalanine/5 mL; consult your health care provider.
  • Consult physician at once if watery and bloody stools (with or without stomach cramps and fever) develop.
  • Consult health care provider if hypoglycemic reactions occur during therapy 


Enter Buying Requirement Details
Email Id
Mobile number

Other Products in 'Pharma Tablets' category



Back to top
trade india member
MEDILON HEALTHCARE All Rights Reserved.(Terms of Use)
Developed and Managed by Infocom Network Private Limited.